Caris Life Sciences (CAI) Depreciation & Amortization (CF) (2024 - 2026)

Caris Life Sciences' Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 27.64% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $20.6 million (down 45.92% YoY), while the FY2025 annual figure was $22.6 million, down 53.8% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $5.1 million, up from $4.3 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $11.6 million in Q2 2024, with the low at $4.3 million in Q4 2025.
• The 3-year median for Depreciation & Amortization (CF) is $6.7 million (2025), against an average of $7.4 million.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) tumbled 53.33% in 2025, then decreased 27.64% in 2026.
• Caris Life Sciences' Depreciation & Amortization (CF) stood at $9.1 million in 2024, then sank by 52.83% to $4.3 million in 2025, then advanced by 18.45% to $5.1 million in 2026.
• Business Quant data shows CAI's Depreciation & Amortization (CF) at $5.1 million in Q1 2026, $4.3 million in Q4 2025, and $4.9 million in Q3 2025.